Another of the great meetings we had at BPI in Boston was with Tom Ransohoff of the biomanufacturing partner, Resilience and he told us something about their business and the changes he’s seen since starting out.
Resilience is a biomanufacturing innovation partner, leading the pursuit of novel medicines by revolutionizing how they’re made, funded and scaled. The technology of manufacturing complex medicines, like cell and gene therapies, hasn’t kept pace with the wave of scientific discoveries fueling them. Resilience brings together scientists and engineers with access to the most advanced technologies to support, and in collaboration between academia, biopharma and governments to improve the way complex medicines are made.
Hear our discussion about:
- what’s driving the current trend in derivatization of biomolecules
- what life is like for a manufacturer working with newer, more complex product types and modalities
- and where the pharma industry might be in five to ten years from now?
About Tom Ransohoff
Thomas Ransohoff has over 30 years of experience in the biopharmaceutical industry with particular expertise in development and scale-up of biopharmaceutical processes; separations and purification technologies; cGMP manufacturing; and management of technology-based start-up ventures. Before joining Resilience, Mr. Ransohoff was a Managing Director at BDO and its precursor BPTC, a leading CMC consulting firm that he helped build over a 20 year period. Prior to that, he held senior level positions at TranXenoGen, Dyax, Repligen, and Xoma. He is also a co-founder of several successful start-ups, including 4th Dimension Bioprocess, Tarpon Biosystems and BioFlash Partners. He serves on a number of scientific and professional advisory boards and holds a Bachelor’s degree from MIT and a Master’s degree from the University of California, Berkeley, both in Chemical Engineering.
